What are the current options for Amyloid light-chain Amyloidosis treatment?
How many companies are developing therapies for the treatment of AL Amyloidosis?
How many are Amyloid light-chain Amyloidosis emerging therapies in the early-stage, mid-stage, and late stages of development for the treatment of AL Amyloidosis?
What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and significant licensing activities that will impact the Amyloid light-chain Amyloidosis market?
Which are the dormant and discontinued products and the reasons for the same?
What is the unmet need for current therapies for the treatment of AL Amyloidosis?
What are the current novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing Amyloid light-chain Amyloidosis therapies?
10 Figures In Biotech Revolutionizing Treatment Of Neurological Disorders
wonderfulengineering.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wonderfulengineering.com Daily Mail and Mail on Sunday newspapers.
Cogent Biosciences Appoints Accomplished Finance Executive Todd E Shegog to its Board of Directors
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
A Behind The Scenes Look Into Enanta s CEO, Jay Luly
Source: Life Science Leader
Follow Me On Twitter @RfwrightLSL
Jay Luly, Ph.D., president and CEO, Enanta Pharmaceuticals
“I grew up in Illinois,” shares Jay Luly, Ph.D., CEO of Enanta Pharmaceuticals. Luly is being interviewed for a future feature in
Life Science Leader, and I started the conversation with a little ice breaker. Luly shares that somewhere along the way in high school, he figured out he wanted to study chemistry. Turns out the University of Illinois (U of I) had one of the strongest chemistry departments in the country at that point. “So many kids go on college trips, and it blows me away with how many schools they might visit today,” he states. But for him, U of I was very obvious, as it was a great school, proximal, and affordable. Upon completion of his undergrad, Luly moved to the West Coast to pursue a Ph.D. from the University of California, Berkeley. “That was my first foray to the Bay area.”
I
In the now ubiquitous computer-generated image of the SARS-CoV-2 virus that has ricocheted around the world in the year since it was created at the Centers for Disease Control and Prevention, it is the virusâs âspikeâ proteins that catch the eye. Rendered in lurid red-orange, the spikes bristle like a dense forest on the barren, gray surface of a distant planet, in both color and form embodying the dread and sorrow that COVID has unleashed upon humanity.
But the spikes of SARS-CoV-2 would be no more than a biological curiosity were it not for a less-familiar protein called ACE2, which provides the portal through which the virus enters our cells to hijack them for its own ends.